Organization
PT Bio Farma
15 clinical trials
Clinical trial
Comparison of Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B at Birth Dose Using New Hepatitis B Bulk (Bio Farma), in Indonesian InfantsStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
Immunogenicity and Safety Following In-House Recombinant Hepatitis B (Bio Farma) Vaccine Compared to Hepatitis B (Bio Farma)® Vaccine in Indonesian PopulationStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
Safety and Tuberculin Conversion Following BCG Vaccine Vial (Bio Farma) Compared to Registered BCG Vaccine (Bio Farma) in Indonesian InfantsStatus: Completed, Estimated PCD: 2022-05-31
Clinical trial
A Phase III, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Aged 12-17 Years in IndonesiaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Adults, Adolescent, Children and InfantsStatus: Active (not recruiting), Estimated PCD: 2024-10-28
Clinical trial
Protectivity and Safety Following Recombinant Hepatitis B Vaccine With Different Source of Hepatitis B Bulk Compared to Hepatitis B (Bio Farma) Vaccine in Indonesian PopulationStatus: Completed, Estimated PCD: 2020-01-30
Clinical trial
Immunogenicity and Safety of IndoVac® as a Heterologous Booster Dose Against COVID-19 in Children 12-17 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2023-06-22
Clinical trial
A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Adjuvanted With Alum+CpG 1018) in Healthy Populations Aged 18 Years and Above in IndonesiaStatus: Completed, Estimated PCD: 2022-08-02
Clinical trial
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Bio Farma) Adjuvanted With Alum+CpG 1018 in Healthy Populations Aged 18 Years and Above in IndonesiaStatus: Completed, Estimated PCD: 2022-07-22
Clinical trial
Immunogenicity & Safety of IndoVac® as a Homologous Booster Dose Against COVID-19 in Adults Aged 18 Years and Above in IndonesiaStatus: Not yet recruiting, Estimated PCD: 2023-11-01
Clinical trial
Safety Profile Following Moderna COVID-19 Primary Vaccine in Healthy Adults Aged ≥ 18 Years in IndonesiaStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
Safety Profile of Diphtheria Antitoxin (DAT) in IndonesiaStatus: Completed, Estimated PCD: 2023-05-13
Clinical trial
Immunogenicity & Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Bio Farma) Adjuvanted With Alum+CpG 1018 Compared to Registered Covid-19 Vaccine (Covovax - Protein Subunit Vaccine) in Healthy Populations Aged 18 Years and Above in Indonesia (Phase III)Status: Completed, Estimated PCD: 2022-08-05
Clinical trial
Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates, Lot to Lot Consistency and Antigen Interference With Co-Administered EPI Vaccines (Phase III)Status: Completed, Estimated PCD: 2022-04-30
Clinical trial
Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients in Multicenter, Non-randomized, Open-label, Non-inferiority TrialStatus: Recruiting, Estimated PCD: 2023-11-30